Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : MOMO MOMMA's -- Ignore unavailable to you. Want to Upgrade?

To: Wayne Rumball who wrote (684)	7/13/1998 10:45:00 AM
From: CoffeePot	Read Replies (1) \| Respond to of 1051

SALV @1/8 the next BICO..near 52wk low .Book .05 debt/equity..05 Float 22mm Shares OS 28mm SALV is engaged in the development, manufacture and marketing of rapid immunoassays for use in the detection of infectios diseases. SALV also distributes medical specimen collection devices. For the nine months ended 9/97, revenues totalled $1 million, up from $480 thousand. Net loss increased 12% to $3.8 million. Revenues reflect increasing demand for the Company's rapid testing systems. Higher loss reflects increased manufacturing overhead and a $194 thousand restructuring expense.